Alder BioPharmaceuticals, Inc.
11804 North Creek Parkway South
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody administered quarterly via infusion that allows for 100% of the dose available to selectively and potently inhibit the calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Stock Symbol: ALDR
Stock Exchange: NASDAQ
107 articles with Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals® Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine
Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate 43% of patients receiving 300 mg of eptinezumab achieved a 75% or greater reduction of monthly migraine days
Alder BioPharmaceuticals® Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine
Data presented today at the American Headache Society (AHS) Annual Scientific Meeting demonstrate eptinezumab’s robust efficacy is further improved at one year following third and fourth quarterly infusions
Alder BioPharmaceuticals® to Present New Data Further Highlighting Eptinezumab’s Efficacy Profile for Migraine Prevention at American Headache Society Meeting
Alder BioPharmaceuticals, Inc. announced that it will present updated data from the PROMISE 1 and PROMISE 2 phase 3 clinical trials for eptinezumab, Alder's lead investigational product candidate for migraine prevention, at the upcoming American Headache Society (AHS) annual scientific meeting
5/18/2018Amgen and Novartis scored a big win in the migraine market late Thursday when the U.S. Food and Drug Administration approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
This year’s American Academy of Neurology meeting in Los Angeles has revealed positive news that can benefit patients across a wide variety of indications.
Amgen announced final data from its Phase IIIb LIBERTY clinical trial of Aimovig (erenumab), with positive results likely to lead to a blockbuster drug for migraine sufferers.
Biohaven Pharmaceutical released positive top-line results from two Phase III clinical trials of rimegepant for migraine. Despite the positive data, shares were down more than 30 percent in early trading this morning.
3/21/2018Alder BioPharmaceuticals announced that Randall Schatzman, the company’s president, chief executive officer and director, will be stepping down.
Alder BioPharmaceuticals, Inc. Announces Exercise in Full of Underwriters’ Option to Purchase Additional 2.50% Convertible Senior Notes Due 2025
The sale of additional Notes closed on February 13, 2018.
2/2/2018Alder intends to use the cash to fund the development and commercialization of eptinezumab.
The sale of the Notes is expected to close on February 1, 2018, subject to the satisfaction of customary closing conditions.
The Notes will be unsecured senior obligations of Alder. Interest will be payable semi-annually in arrears.
With the J.P. Morgan Healthcare Conference now over, some analysts are looking back and picking out the "winners and losers" from the conference.
On Jan. 8, Alder BioPharma announced that its eptinezumab met its primary endpoint in its Phase III PROMISE 2 clinical trial for preventing migraine.
Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase III Trial for Chronic Migraine Prevention
The primary endpoint met: reduction of 8.2 monthly migraine days from baseline compared to 5.6 days for placebo.
Alder intends to use the cash to fund payments under Alder’s European patent settlement and global license agreement with Teva announced today.
Research and development expenses for the quarter ended September 30, 2017 totaled $52.2 million, compared to $29.5 million for the same period in 2016.
Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2017 Financial and Operating Results
Conference call set for 5:00 p.m. EST November 7, 2017.
Alder BiopharmaTo Present Data From Eptinezumab Development Program At 18th Congress Of The International Headache Society